InvestorsHub Logo
Followers 2
Posts 456
Boards Moderated 0
Alias Born 02/21/2012

Re: None

Thursday, 01/10/2019 5:53:04 PM

Thursday, January 10, 2019 5:53:04 PM

Post# of 430655
Any buyout could be small potatoes versus licensing agreements with MULTIPLE big pharmas at the same time... :

Given that Vascepa is to be prescribed on top of statin therapy, combo pills will emerge at some point.

I find it an intriguing and potentially most accretive strategy for AMRN to manufacture combo pills with Crestor, Lipitor etc and then comarket the combos alongside the large pharma sales forces. Big pharma would get their beloved brands back from the generics and the AMRN salesforce would in essence be bigger than that of any single big pharma.

Or maybe license Vascepa to them and they create their own combo pills.

Or AMRN could be sold to a consortia of big pharma so that they could each go to market with their own combo pill.

Unique deals but Vascepa is a unique drug!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News